BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Stereotaxis, Inc. (STXS) Epoch(TM) Solution's Momentum Drives Strong Presence at the Heart Rhythm Society (HRS) Annual Meeting


5/8/2012 10:09:09 AM

ST. LOUIS, May 7, 2012 /PRNewswire/ -- Stereotaxis, Inc. (NASDAQ: STXS) will highlight clinical results from the first 1,250 cases and the latest innovations for the Epoch platform, its new generation comprehensive solution for the electrophysiology (EP) laboratory, at the 33rd Annual Heart Rhythm Society (HRS) Scientific Sessions, May 9-12, 2012.

The formal HRS academic program features multiple invited presentations, podium presentations, and posters detailing Stereotaxis' clinical results in a wide variety of arrhythmias. A total of 11 invited podium presentations feature use of Stereotaxis magnetic navigation technology. In addition, 13 submitted abstracts that feature or discuss Stereotaxis technology are included in this year's HRS program. Highlights of these submitted abstracts include comparative data on VT ablation, multi-center VT data, lesion formation, pediatric outcome data, and the first large series of Vdrive system's clinical outcomes data.

Stereotaxis will be at booth number 1307, providing demonstrations of commercially available products and a technical suite for obtaining input on new product innovations from select physician customers. In addition, the Company will feature at the booth a speaker series where customers will share their experiences with the Epoch and Odyssey product platforms. In-booth speakers include:

  • Dr. Robert Schweikert from Akron General Medical Center on the Odyssey Solution (May 10 at 9:30 am ET);
  • Dr. Yaariv Khaykin from Southlake Regional Health Center on the Odyssey Solution (May 10 at 10:00 am ET); and
  • Dr. J. Peter Weiss from Intermountain Medical Center on the Epoch Solution (May 10 at 3:45 pm ET and May 11 at 10:00 am ET).

Stereotaxis will unveil a broad number of product innovations for the Niobe® ES, Vdrive and Odyssey platforms scheduled to be shipped in 2012. The innovations include advancements in linear line formation and testing, Vdrive offering and Odyssey remote collaboration.

"Stereotaxis will launch exciting advancements at the upcoming HRS congress, which will further enhance the value we bring to the EP market," said Michael P. Kaminski, President and Chief Executive Officer of Stereotaxis. The 2012 innovations for the Niobe® ESand Odyssey product platforms as well as the new Vdrive platform demonstrate our continued commitment to providing new solutions for the EP market."

About Stereotaxis

Stereotaxis is a healthcare technology and innovation leader in the development of robotic cardiology instrument navigation systems designed to enhance the treatment of arrhythmias and coronary disease, as well as information management solutions for the interventional lab. With over 100 patents for use in a hospital's interventional surgical suite, Stereotaxis helps physicians around the world provide unsurpassed patient care with robotic precision and safety, improved lab efficiency and productivity, and enhanced collaboration of life-saving information. Stereotaxis' core technologies are the Niobe® ES Remote Magnetic Navigation system, the Odyssey portfolio of lab optimization, networking and patient information management systems and the Vdrive Robotic Mechanical Navigation system and consumables.

The core components of Stereotaxis systems have received regulatory clearance in the U.S., Europe, Canada and elsewhere; the V-Loop circular catheter manipulator is currently under regulatory review by the U.S. Food and Drug Administration. For more information, please visit www.stereotaxis.com and www.odysseyexperience.com.

This press release includes statements that may constitute "forward-looking" statements, usually containing the words "believe," "estimate," "project," "expect" or similar expressions. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, our continued access to capital and financial resources, including our ability to extend our current loan facility and to obtain additional capital through other financing arrangements, in each case on a timely basis and on terms that are acceptable, continued acceptance of the Company's products in the marketplace, the effect of global economic conditions on the ability and willingness of customers to purchase our systems and the timing of such purchases, the outcome of various shareholder litigation recently filed against us, competitive factors, changes resulting from the recently enacted healthcare reform in the U.S., including changes in government reimbursement procedures, dependence upon third-party vendors, timing of regulatory approvals, and other risks discussed in the Company's periodic and other filings with the Securities and Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release. There can be no assurance that the Company will recognize revenue related to its purchase orders and other commitments in any particular period or at all because some of these purchase orders and other commitments are subject to contingencies that are outside of the Company's control. In addition, these orders and commitments may be revised, modified, delayed or canceled, either by their express terms, as a result of negotiations, or by overall project changes or delays.

SOURCE Stereotaxis, Inc.



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES